Finance

Lists
Why is CCCC down 6.05%?
Dive Deeper
CCCC:NASDAQ
C4 Therapeutics, Inc
$2.95
-6.05%
(-0.19) 1D
$3.00
+1.82% (+0.054)
After hours
Closed: Oct 2, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CCCC...
Open
$3.19
High
$3.33
Low
$2.93
Mkt. cap
362.92M
Avg. vol.
2.08M
Volume
3.38M
52-wk high
$5.17
52-wk low
$1.69
EPS
-$1.00
Beta
3.08
Shares outstanding
123.02M
No. of employees
104
Open
$3.19
High
$3.33
Low
$2.93
Mkt. cap
362.92M
Avg. vol.
2.08M
Volume
3.38M
52-wk high
$5.17
52-wk low
$1.69
EPS
-$1.00
Beta
3.08
Shares outstanding
123.02M
No. of employees
104
News stories
From web sources and news partners
About C4 Therapeutics, Inc
CEO-
Employees104
Founded2015
HeadquartersWatertown, Massachusetts, United States
SectorBiotechnology
Websitec4therapeutics.com
Analyst ratings
Based on 3 analysts giving stock ratings to CCCC in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for CCCC in the last 3 months.
Highest
Current $2.95
$10.00 (+238.98%)
Average
$8.50 (+188.14%)
Lowest
$7.00 (+137.29%)
Analyst
Recommendation
Action
Price target
Projected
Date
Derek Archila
Wells Fargo
Buy
Reiterated
$10.00
+239%
08/12/2026
Etzer Darout
Barclays
Buy
Maintained
$7.00
+137.3%
08/12/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
08/11/2026
Akash Tewari
Jefferies
Buy
Maintained
$14.00
+374.6%
04/30/2026
Unknown Analyst
Jefferies
Buy
Maintained
$14.00
+374.6%
04/10/2026
Bradley Canino
Guggenheim
Buy
Reiterated
$7.00
+137.3%
02/26/2026
Leah R. Cann
Brookline Capital Markets
Buy
Maintained
$30.00
+916.9%
02/23/2026
Last report
Aug 11, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.18 / -$0.23
+21.74%beat
Revenue / Est. (USD)
6.64M / 4.00M
+66.02%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
11.23M
11.02M
6.15M
6.64M
Cost of goods sold
25.99M
-70.28M
24.61M
24.47M
Cost of revenue
25.99M
-70.28M
24.61M
24.47M
Research and development expenses
-
95.26M
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.92M
9.18M
9.33M
8.59M
Operating expense
8.92M
104.44M
9.33M
8.59M
Total operating expenses
34.91M
34.16M
33.94M
33.06M
Operating income
-23.68M
-23.14M
-27.78M
-26.42M
Other non operating income
-
-
-
-
EBT including unusual items
-32.17M
-20.36M
-25.13M
-23.64M
EBT excluding unusual items
-21.43M
-21.23M
-26.22M
-23.64M
Income tax expense
-
121.00K
-
-
Effective tax rate
-
-0.59%
-
-
Other operating expenses
-
-
-
-
Net income
-32.17M
-20.49M
-25.13M
-23.64M
Net profit margin
-286.43%
-185.97%
-408.47%
-355.90%
Earnings per share
-0.30
-0.18
-0.20
-0.18
Interest and investment income
2.25M
1.92M
1.57M
2.79M
Interest expense
-
-
-
-
Net interest expenses
2.25M
1.92M
1.57M
2.79M
Depreciation and amortization charges
-
-
-
-
EBITDA
-23.22M
-22.72M
-27.38M
-26.13M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps